Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
EXAGEN INC. | Director | Stock Option(right to buy) | 9K | Jun 9, 2023 | Direct | ||
Reneo Pharmaceuticals, Inc. | Chief Development Officer | Common Stock | 0 | $6.28 | Jul 14, 2021 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
XGN | EXAGEN INC. | Jun 9, 2023 | 1 | $0 | 4 | Jun 13, 2023 | Director |
XGN | EXAGEN INC. | Jun 16, 2022 | 1 | $0 | 4 | Jun 21, 2022 | Director |
XGN | EXAGEN INC. | Sep 3, 2021 | 1 | $14K | 4 | Sep 7, 2021 | Director |
RPHM | Reneo Pharmaceuticals, Inc. | Jul 14, 2021 | 1 | -$950K | 4 | Jul 15, 2021 | Chief Development Officer |
RPHM | Reneo Pharmaceuticals, Inc. | Jul 8, 2021 | 2 | $220K | 4 | Jul 9, 2021 | Chief Development Officer |
XGN | EXAGEN INC. | Jun 17, 2021 | 1 | $0 | 4 | Jun 21, 2021 | Director |